Vitiligo
Not recruitingStudy on MK-6194 for Treating Adults with Non-Segmental Vitiligo
Study on MK-6194 for Treating Adults with Non-Segmental Vitiligo
Belgium- Participants:18–64 years · 65+ years
- Substances:MK-6194
- Sponsor:Merck Sharp & Dohme LLC
Rare diseases
Investigational molecules
Locations
Back to Belgium1 979 clinical trials in Kessel-Lo, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.
Study on MK-6194 for Treating Adults with Non-Segmental Vitiligo
BelgiumStudy of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment
BelgiumStudy Comparing Short-Course Radiotherapy and Drug Combination for Older Patients with Locally Advanced Rectal Cancer
BelgiumStudy on Lenalidomide, Tafasitamab, and Rituximab for Treating Diffuse Large B-Cell Lymphoma in Patients Aged 80 and Older
BelgiumStudy on Radiprodil for Seizures and Behavioral Symptoms in Patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II
BelgiumStudy on Mirikizumab for Children and Teens with Moderate to Severe Ulcerative Colitis
BelgiumStudy of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma
BelgiumStudy on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy
BelgiumStudy on Guselkumab and Etanercept for Treating Chronic Plaque Psoriasis in Children Aged 6 to 17 Years
BelgiumStudy Comparing Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in Adults New to Antiretroviral Therapy
BelgiumStudy of BMS-986466 with Adagrasib and Cetuximab for Patients with KRAS G12C-mutant Advanced Solid Tumors
BelgiumStudy on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19
BelgiumThe busiest research cities in the country
What the registry says about research in the country
Innovative clinical trials focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. This research explores alternative treatment approaches for common digestive conditions.
The study evaluates various therapeutic approaches, including on-demand medication and alginate-based alternatives, to optimize treatment protocols for patients with digestive disorders.
Research examining optimal medication reduction strategies in primary care settings, with a focus on improving long-term patient outcomes and reducing unnecessary medication use.
This initiative aims to establish evidence-based guidelines for discontinuing long-term medications when they may no longer be clinically indicated.
Comparative research evaluating the effectiveness of different deprescribing approaches in managing common gastrointestinal conditions.
The research compares traditional dose reduction methods with newer therapeutic strategies to determine optimal treatment pathways.
Tell us about your condition – we search every trial in Europe and connect you with the right site.